速递｜明星口服减重药误当作“美容捷径”！专家这样提醒

Core Viewpoint - The article discusses the recent approval of oral semaglutide, a GLP-1 class drug, by the FDA for weight management, highlighting its potential to simplify weight loss efforts while emphasizing that weight loss is not merely about taking a pill [6]. Mechanism of Action - Semaglutide works by activating GLP-1 receptors, promoting insulin secretion, inhibiting glucagon release, and delaying gastric emptying, which collectively reduce hunger and food intake [8]. - The oral formulation requires higher doses due to lower absorption efficiency in the gastrointestinal tract and has specific administration requirements, such as taking it on an empty stomach [8]. Clinical Indications - Current weight loss prescription drugs in China primarily consist of GLP-1 medications, suitable for individuals with a BMI ≥ 28 or BMI ≥ 24 with obesity-related conditions [9]. - The only non-prescription weight loss drug available is orlistat, which has notable tolerance and side effect issues [9]. Emerging Weight Loss Drugs - New generation weight loss drugs targeting multiple pathways show promise for better weight control and metabolic improvement, but their long-term safety and tolerability need further observation [9]. - The emergence of oral formulations raises concerns about potential misuse among individuals not meeting the clinical indications, particularly those with normal weight seeking rapid weight loss [9]. Weight Management Strategy - Weight management should focus on preserving muscle mass and maintaining metabolic health, with adequate protein intake, resistance training, and good sleep being essential for sustainable weight management [10]. - Medications should be used under medical supervision, with a clear strategy for maintaining weight after discontinuation to avoid misconceptions about weight loss drugs as quick fixes [10].